Corium is a biopharmaceutical company focused on developing innovative neuroscience therapies aimed at enhancing treatment options for patients, their families, and caregivers. The company is committed to advancing the standards of care through its product offerings, which include AZSTARYS® and ADLARITY®. AZSTARYS® combines serdexmethylphenidate and dexmethylphenidate, providing a novel approach to treating attention-deficit/hyperactivity disorder (ADHD). ADLARITY® is a transdermal system for delivering donepezil, a medication used in the management of Alzheimer's disease. These products reflect Corium's dedication to addressing significant therapeutic needs in the neuroscience field.

Corium's focus on innovative delivery systems is evident in its transdermal technology, which allows for sustained medication release and improved patient compliance. By leveraging advanced formulations and delivery methods, Corium aims to provide effective treatment options that are both convenient and beneficial for patients. The company's ongoing research and development efforts underscore its commitment to transforming care in the neuroscience domain, ensuring that clinicians have access to cutting-edge therapies that can significantly impact patient outcomes.

United States

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers.  Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

Corium

Company Details